Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 is a new market research publication announced by Reportstack. The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.
Ticagrelor was approved for use in the EU in December 2010 (AstraZeneca, press release, December 6, 2010) under the brand name Brilique. In July 2011, the FDA approved ticagrelor for use in the US under the brand name Brilinta (AstraZeneca, press release, July 20, 2011). Brilinta is indicated for use in patients during the acute phase of ACS, along with standard aspirin therapy, at a loading dose of 180mg. During the chronic treatment phase, 90mg doses are taken twice daily with maintenance doses of aspirin not to exceed 100mg.
Scope
- Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Aricept for the top seven countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for ACS
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Aricept performance
- Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)To view the table of contents and know more details please visit Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
Ticagrelor was approved for use in the EU in December 2010 (AstraZeneca, press release, December 6, 2010) under the brand name Brilique. In July 2011, the FDA approved ticagrelor for use in the US under the brand name Brilinta (AstraZeneca, press release, July 20, 2011). Brilinta is indicated for use in patients during the acute phase of ACS, along with standard aspirin therapy, at a loading dose of 180mg. During the chronic treatment phase, 90mg doses are taken twice daily with maintenance doses of aspirin not to exceed 100mg.
Scope
- Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Aricept for the top seven countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for ACS
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Aricept performance
- Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)To view the table of contents and know more details please visit Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
No comments:
Post a Comment